Literature DB >> 15178330

Estrogen receptor activation at serine 305 is sufficient to upregulate cyclin D1 in breast cancer cells.

Seetharaman Balasenthil1, Christopher J Barnes, Suresh K Rayala, Rakesh Kumar.   

Abstract

Recent studies have shown that p21-activated kinase 1 (Pak1) phosphorylates estrogen receptor-alpha (ER alpha) at Ser 305 and also promotes its transactivation function. Here, we sought to investigate whether substitution of serine 305 in ER with glutamic acid (ER alpha-S305E), which mimics the phosphorylation state, would influence the status of ER-target genes. To explore this possibility, we generated clones overexpressing ER alpha-S305E in ER-negative MDA-MB-231 cells and analyzed the status of ER-regulated genes using a gene array. Results indicated that the expression of ER alpha-S305E is sufficient to upregulate the expression of a few but not all ER-regulated genes, i.e., cyclin D1 and zinc finger protein 147 (estrogen-responsive finger protein), while there was no significant change in the expression of remaining genes on the array. In addition, we found an increased expression as well as nuclear accumulation of cyclin D1 protein in MDA-MB-231 cells expressing ER alpha-S305E as compared to the level of cyclin D1 in MDA-MB-231 cells expressing WT-ER alpha or pcDNA. Furthermore, ER alpha-S305E, but not mutation of ER alpha-S305 to alanine, enhanced the cyclin D1 promoter activity. These findings suggest that ER alpha activation at S305 is sufficient to upregulate the expression of cyclin D1, an ER-regulated gene that is implicated in the progression of breast cancer. Phosphorylation of ER alpha by Pak1 or its upstream regulators could upregulate the expression of a subset of ER-target genes in a ligand-independent manner and hence, might contribute toward the development of hormone independence in breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15178330     DOI: 10.1016/j.febslet.2004.04.071

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  24 in total

1.  Opposing action of estrogen receptors alpha and beta on tumor necrosis factor-alpha gene expression and caspase-8-mediated apoptotic effects in HA22T cells.

Authors:  Erh-Jung Huang; Cheng-Chung Wu; Shin-Da Lee; Juen-Hau Chen; Jer-Yuh Liu; Jiunn-Liang Ko; James A Lin; Min-Chi Lu; Li-Mien Chen; Chih-Yang Huang; Wei-Wen Kuo
Journal:  Mol Cell Biochem       Date:  2006-04-22       Impact factor: 3.396

Review 2.  Molecular pathways: targeting p21-activated kinase 1 signaling in cancer--opportunities, challenges, and limitations.

Authors:  Jeyanthy Eswaran; Da-Qiang Li; Anil Shah; Rakesh Kumar
Journal:  Clin Cancer Res       Date:  2012-05-17       Impact factor: 12.531

Review 3.  Integration of the extranuclear and nuclear actions of estrogen.

Authors:  Ellis R Levin
Journal:  Mol Endocrinol       Date:  2005-02-10

Review 4.  GPR30: A G protein-coupled receptor for estrogen.

Authors:  Eric R Prossnitz; Jeffrey B Arterburn; Larry A Sklar
Journal:  Mol Cell Endocrinol       Date:  2007-01-11       Impact factor: 4.102

5.  Pregnane X Receptor-Humanized Mice Recapitulate Gender Differences in Ethanol Metabolism but Not Hepatotoxicity.

Authors:  Krisstonia Spruiell; Afua A Gyamfi; Susan T Yeyeodu; Ricardo M Richardson; Frank J Gonzalez; Maxwell A Gyamfi
Journal:  J Pharmacol Exp Ther       Date:  2015-07-09       Impact factor: 4.030

6.  Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study.

Authors:  Thomas P Ahern; Deirdre P Cronin-Fenton; Timothy L Lash; Henrik Toft Sørensen; Anne Gulbech Ording; Stephen J Hamilton-Dutoit; Ylva Hellberg
Journal:  Acta Oncol       Date:  2016-04-08       Impact factor: 4.089

7.  Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer.

Authors:  Adena E Rosenblatt; Maria Ines Garcia; Leah Lyons; Yingqiu Xie; Carol Maiorino; Laurent Désiré; Joyce Slingerland; Kerry L Burnstein
Journal:  Endocr Relat Cancer       Date:  2011-02-23       Impact factor: 5.678

Review 8.  Pathways to tamoxifen resistance.

Authors:  Rebecca B Riggins; Randy S Schrecengost; Michael S Guerrero; Amy H Bouton
Journal:  Cancer Lett       Date:  2007-05-01       Impact factor: 8.679

9.  A hypersensitive estrogen receptor alpha mutation that alters dynamic protein interactions.

Authors:  Matthew H Herynk; Torsten Hopp; Yukun Cui; Airu Niu; Arnoldo Corona-Rodriguez; Suzanne A W Fuqua
Journal:  Breast Cancer Res Treat       Date:  2009-10-20       Impact factor: 4.872

Review 10.  Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.

Authors:  Grazia Arpino; Lisa Wiechmann; C Kent Osborne; Rachel Schiff
Journal:  Endocr Rev       Date:  2008-01-23       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.